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The complications of clinical cardiac electrophysiologic
studies were prospectively evaluated in 1,000 consecutive
patients studied in one laboratory with an unaltered pro-
tocol to better assess the risks of this procedure. There
were 728 men and the mean age of the entire group was
58 years (range 16 to 84). Coronary artery disease was
the most common type of heart disease (56%) and 200
patients had no identifiable organic heart disease. The
indication for study was a ventricular tachyarrhythmia
or cardiac arrest in 582 patients. Each patient underwent
an initial (baseline) study and 444 patients underwent
serial drug studies (2.7/patient).
There was one death during these studies. Other ma-
jor complications Included arterial injury (0.4 %),
thrombophlebitis (0.6%), systemic arterial embolism
During the past decade, clinical electrophysiologic studies
have become an accepted part of the diagnostic evaluation
of patients with serious arrhythmias (1-5) . Particularly in
patients with malignant arrhythmias, selection of therapy
by electrophysiologic techniques has resulted in a reduction
in the incidence of recurrent arrhythmia and sudden death
(6- 10). Despite the increasingly wide application of this
procedure. there is little information about the mortality.
morbidity and risks associated with it. Therefore. we pro-
spectively collected these data in patients undergoing elec-
trophysiologic studies performed with a standardized pro-
cedure in a single laboratory.
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(0.1 %), pulmonary embolism (0.3%) and cardiac per-
foration (0.2 %). Significant arrhythmic complications
included catheter-induced permanent complete atrio-
ventricular (AV) block in 1 patient, nonclinical atrial
fibrillation that required therapy in 10 patients and se-
vere proarrhythmic events in 12 (3%) of 397 patients
undergoing drug studies for ventricular tachyarrhyth-
mias. Cardioversion was required for termination of
ventricular tachyarrhythmias in 179baseline studies (53%
of patients with inducible arrhythmia), and in an ad-
ditional 35 patients, cardioversion was required at least
once during follow-up studies. Although clinical cardiac
electrophysiologic studies are associated with compli-
cations, the risks are small and acceptable.
(J Am Coli CardioI1987;9:1261-8)
Methods
Study patients. The data were prospectively collected
between October 27, 1981 and February 7, 1986 and rep-
resent a consecutive series of the initial 1.000 patients stud-
ied in this laboratory. Our procedures were unchanged dur-
ing this period. The patients ' clinical history and demographic
data, methodologic details of the procedures, results and
complications of the studies and other pertinent data were
prospectively collected in a computerized data base. All
records of patients who developed complications and a ran-
dom selection of the hospital charts of 25% of the patients
were reviewed to assure accuracy.
This series includes 1,000 consecutive patients who
underwentan initial clinical electrophysiologic study. In444
of the patients, one or more follow-up drug studies were
performed. There were 728 men and 272 women; their ages
ranged from 16 to 84 years (mean 58). The types of un-
derlying heart disease and indications for electrophysiologic
study are shown in Tables I and 2.
Electrophysiologic procedures. All procedures were
performed in a catheterization laboratory used solely for
0735~ 1097/87/$3.50
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Table 1. Type of Underlying Heart Disease in
1,000 Patients
No. of
Patients
Table 2. Indications for Clinical Electrophysiologic Studies in
1,000 Patients
*Hypertrophic (n = 21) ordilated congestive (n =
139) cardiomyopathy not related to coronary artery dis-
ease. tNot related to coronary artery disease. :j:lncludes
mitral valve prolapse without hemodynamically signif-
icant mitral regurgitation. MI = myocardial infarction.
neously by the Seldinger technique or by cutdown under
local anesthesia(bupivacaine, 0.25%) and positioned under
fluoroscopic observation. Aftercatheterswere inserted, hep-
arin was administered in a 2,500 U bolus followed by an
infusionof 500 U/h for the duration of the study. If arterial
catheterization was performed, an additional 2,500 U bolus
of heparin was given and the continuous infusion was in-
creased to 1,000 U/h. Anticoagulation was not reversed
unless arterial catheterization was performed, in which case
protamine was given.
After each laboratory session, catheters were removed
and hemostasis was obtained. Patients remained at bed rest
for 12 hours after each procedure (overnight if arterial cath-
eterization was performed). Catheters were not left in po-
sition for drug studies but were inserted for each laboratory
visit.
Catheters were reused a maximum of 10 times. Before
reuse theyunderwent a rigorous procedure of cleaning, checks
of mechanical and electrical integrity and gas sterilization.
Initial studies. These includedevaluationof atrial, atrio-
ventricular (AV) conduction system and ventricular elec-
trophysiologic variables. Unless vascular access was lim-
ited, three catheters were used in an initial study. Initial
studies were performed after antiarrhythmic drugs had been
discontinued for five drug half-lives in 980 patients. In 20
patients, ventriculartachyarrhythmias were so frequent that
no drug-free interval could be obtained and the initial study
was performed while the patient was on an antiarrhythmic
regimen.
Drug testing. After the initial study, drug tests (follow-
up studies) were performed in most patients with inducible
paroxysmal supraventricular tachycardia, sustainedventric-
ular tachycardia or ventricular fibrillation. Drugs were ad-
ministered intravenously or orally and programmedelectri-
cal stimulation was performed. A single drug and, at most,
one combination regimen were evaluated in each laboratory
session. Evaluationof each drug regimen was considered a
follow-up study even if it was performed in the same lab-
oratory session as the initial study or another drug study.
Recordings. ECG leads and intracardiac electrograms
were obtained with a physiologic recorder (E for M VRI6)
and were recorded on analog magnetic tape (Honeywell
5600C). Real time analog records were obtained on a Min-
gografinkjet recorder. Electricalstimulationwas performed
with a digital stimulatorand optically isolated constantcur-
rent sources (Bloom Associates, Ltd.). The stimulus was a
rectangularpulse delivered at an amplitudeof twice the late
diastolicthreshold. However, theamplitudewasnotallowed
to exceed 10 rnA in the atria and 2 rnA in the ventricles.
Standard protocol ofprogrammed electrical stimulation.
The standard protocol included: 1) atrial and ventricular
pacing at cycle lengths ranging fromjust under that of sinus
rhythm to 300 ms; 2) single atrial extrastimuli delivered
during high right atrial pacing at one or two cycle lengths
563
55
67
441
160
56
21
200
No. of
Patients
Coronary artery disease
No previous MI
Recent (,,;;6 weeks) MI
Remote (>6 weeks) MI
Cardiomyopathy*
Valvular heart diseaset
Congenital heart disease
No structural heart diseaset
electrophysiologic studies. Typically, two physicians, a nurse
and a technician were present during all procedures. Cath-
eter insertion and positioning and programmed stimulation
were performed by a staff electrophysiologist or an electro-
physiology trainee (third year fellow) under direct staff su-
pervision. A staff member was present in the laboratory for
all stimulation procedures.
All patients were studied in the postabsorptive state after
written informedconsent had been given. No premedication
was used; however, intravenousdiazepamwas administered
for mild sedation when necessary during the study. The
electrocardiogram (ECG) was continuously monitoredfrom
the time the patient entered the laboratory until he or she
was returned to the hospital room by laboratory personnel.
Blood pressure was monitored throughout the procedures
by sphygmomanometry.
Woven Dacron catheters (USCI) were inserted percuta-
Sustained monomorphic ventricular tachycardia 239
Nonsustained ventricular tachycardia 206
Cardiac arrest 175
Paroxysmal supraventricular tachycardia 73
Tachycardia orpalpitation ofuncertain type 69
Syncope ofunknown cause 181
AVconduction disturbance 66
Sinus node dysfunction 46
Wolff-Parkinson-White syndrome with tachyarrhythmia 21
Total 1,076*
*Eleven patients had three indications for study and 54 patients had
two indications for study, making a total of 1,076.
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and during sinus rhythm; and 3) single and double ventric-
ular extrastimuli delivered during right ventricular apical
pacing at cycle lengthsof 600 and 450 ms and during sinus
rhythm. In patientswithparoxysmal supraventricular tachy-
arrhythmia or Wolff-Parkinson-White syndrome, or both,
double atrial extrastimuli and left atrial stimulation were
performed. Patients studied for evaluation of ventricular
tachycardia, cardiac arrest or syncope of uncertain origin
underwent administration of triple ventricular extrastimuli
and stimulation at the right ventricular outflow tract. Left
ventricular stimulation was performed in patients who had
sustainedmonomorphic ventriculartachycardia or a cardiac
arrest and in whom right ventricular stimulation had failed
to induce a ventricular tachyarrhythmia (9).
Cardioversion. Whenever sustained arrhythmias were
induced, attempts were made to terminate them with pro-
grammed stimulation. If stimulation techniques were un-
successful, cardioversion was used. If the patient remained
conscious during the arrhythmia, anesthesia with metho-
hexital sodium (Brevital) was administered before cardio-
version.Cardioversion and defibrillation wereaccomplished
with a device that allowedmonitoring of chest wall imped-
ance to assure good electrical contact. Adhesive electrode
pads (R2 pads) were used in the anteroposterior configu-
ration. The initial shock was delivered with a storedenergy
of 60 to 150 J depending on the patient's body size. All
subsequent shocks were delivered at 360 J. If more than
three shocks were required during a study, the study was
terminated for that day.
Definitions. A study-related death was defined as death
that occurred during the study or within 24 hours of the
study and was not attributable to any cause not related to
the procedure, or that was related to a complication of the
study.
Vascular complications were defined as those that oc-
curred within 7 days of the study and required surgical or
other specific therapy (for example, thrombolytic agents) or
resulted in prolongation of hospitalization. This category
included arterial (thrombosis, dissection, rupture and so forth)
and venous (thrombophlebitis, thrombosis) complications,
arteriovenous malformations and hematoma.
Embolic complications included arterial and venous em-
bolism that occurred within 7 days of a procedure or rec-
ognition of vascular complication of a procedure. Arterial
embolization included embolization to the central nervous
system or peripheral or coronary arteries producing clini-
cally recognizable symptoms or signs. Venousembolization
included documented pulmonary embolism and venous
thrombosis in a vein catheterized during the procedure.
Cardiac perforation wasdiagnosed byechocardiographic
demonstration of blood in the pericardial space or by peri-
cardiocentesis during the procedure or immediately after
catheterwithdrawal. It shouldbeemphasized that the serious
vascular, embolic and perforation complications include only
symptomatic events. No studies were performed to identify
asymptomatic events; thus, only clinically significant com-
plications are reported.
Significant hypotension was defined as symptomatic re-
duction in arterial blood pressure that occurred during or
within 24 hours of a procedure and did not respond to leg
raising and an infusion of 250 cc of saline solution.
Standard clinical definitions of angina pectoris, acute
myocardial infarction, congestive heart failure and pneu-
mothorax were used (10). The occurrence of any of these
during or within 24 hours of a procedure was considered a
complication.
An arrhythmic complication of electrophysiologic study
was a bradycardia or tachyarrhythmia that persisted6 hours
after the study or required therapy or both. This definition
excluded the induction of arrhythmias that were clinically
relevant to the patient's indication for study. Our definitions
of induced ventricular tachyarrhythrnias have previously been
published (9).
Results
Catheterization procedures. In the 1,000 initial studies
performed, 2,821 venous catheters were inserted, 2,685
(95%) in the femoral veinsand 133(5%)in the basilicveins.
Three catheters were inserted in subclavian veins. A basilic
vein cutdown was required in seven insertions. There were
32 arterial catheters inserted, all insertedpercutaneously in
femoral arteries. Two patients received five catheters, 124
patients had four, 640 patients had three, 193 patients had
two and 41 patients had one.
Catheters were positioned to recordor stimulate, or both,
in the high right atrium in 998 patients and at the right
ventricular apex in 986. A His bundle electrogram was
recorded in 933 patients. The coronary sinus was catheter-
ized in III patients and the left atrium was entered through
a patent foramen ovale in 8. A catheter was positioned in
the right ventricular outflow tract in 563 patients and in the
left ventricle in 32.
The mean time from the insertion of the first introducer
to removal of catheters was 167 minutes (range 60 to 420)
for initial studies. The mean fluoroscopy time (actual min-
utes of on-time) was 11.6 minutes (range 1.5 to 99) (Fig.
1).
Drug studies. A total of 1,210 follow-up drug studies
were performed in 444 patients (2.7/patient). In 353 pa-
tients, the first drug study was performed on the day of the
initial studyand did not require insertionof additional cath-
eters. In 75 other drug studies, performed on the day of
another drug evaluation, insertion of additional catheters
was not required. In the 782 remaining follow-up drug stud-
ies, 1,001 catheter insertions were required (l.3/patient).
The mean laboratory time for follow-up drug studies that
required catheter insertion was 108 minutes (range 60 to
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Figure1. Total laboratory (A) and fluoroscopy time (B) for 1,000
initial electrophysiologic studies. These histograms show the num-
ber and percent of patients in the respective durations of total
laboratory time (in minutes) and fluoroscopy time (in minutes).
285); the mean fluoroscopy time for these follow-up studies
was 7.0 minutes (range 1 to 62) (Fig. 2).
Arrhythmias. The arrhythmias induced during the ini-
tial studies are presented in Table 3. The majority (89%)
of the drug studies (l,081 of 1,210) were performed in
patients with inducible ventricular tachycardia or fibrilla-
tion.
Figure 2. Total laboratory (A) and fluoroscopy time (B) for fol-
low-up (drug study) electrophysiologic studies. These histograms
show the number and percent of patients in respective durations
of total laboratory time (in minutes) and fluoroscopy time (in
minutes).
Complications (Table 4)
Mortality. One death occurred during these studies. The
patient was a 53 year old man who 5 weeks before study,
had had an acute anterior myocardial infarction that was
complicated by bundle branch block, heart failure, pericar-
ditis and sepsis. Recurrent sustained ventricular tachycardia
began 4 weeks after the infarction and it was unresponsive
to procainamide, lidocaine, quinidine and bretylium alone
and in combinations. The patient was apparently clinically
stable at the time of study and bretylium had been discon-
tinued 48 hours before study. Sustained monomorphic ven-
tricular tachycardia was initiated with double right ventric-
ular apical extrastimuli. The tachycardia cycle length was
280 ms and the systolic blood pressure during tachycardia
was 54 mm Hg. The arrhythmia was terminated with burst
ventricular pacing after 32 seconds. Sinus rhythm resumed;
however, electromechanical dissociation occurred and pro-
longed resuscitative efforts were unsuccessful.
FREQUENCY (PATIENTS) FREQUENCY (PATIENTS)
500 500
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45"1.
400
1% I,.. ICY. .8,.. .,,.. .1".
)60
42"1.
0.L--'-"-',"",-""",,,L.L..u..<~~~~~~~~7":~~"'7':~~
B
100
200
300
1%
241-300
300
100
200
LABORATORY TIME (MIN)
FOLLOW-UP STUDIES
FLUOROSCOPY TIME (MIN)
FOLLOW-UP STUDIES
JACC Vol. 9. No. 6
June 1987:1261-8
HOROWITZET AL.
RISKS OF ELECTROPHYSIOLOGIC STUDIES
1265
*The number of studies in which catheter insertion occurred.
Table 4. Significant Complications of Electrophysiologic
Studies in 1,000 Patients
*At least one arrhythmia was initiated by programmed electrical stimu-
lation in 582 patients.
Table3. Arrhythmias Induced During Initial Electrophysiologic
Studies in 1,000 Patients
(two patients) and fifth laboratory sessions. All six patients
responded to conventional therapywithheparinand warfarin
and no chronic sequelae occurred.
Significant hematomas developed in two patients. One
patient required surgicaldrainage but neither required trans-
fusion. In both, healing occurred without sequelae.
Embolic complications. An arterial embolus was de-
tected in one patient. This patient had had a cardiac arrest,
presumably due to disopyramide, 2 months before initial
electrophysiologic study. Cardiac evaluation revealed only
mitral anular calcification. No arrhythmia was initiated by
programmed stimulation and the left ventricle was not en-
tered. On the day after the study, symptoms of arterial
insufficiency in her leg developed suddenly. A well orga-
nized thrombus was removed from the femoral artery and
there were no sequelae.
Pulmonary embolism occurred in three patients; all had
thrombophlebitis. The embolism was temporally related to
the phlebitis rather than the catheterization procedure. No
patient had severe symptoms and all responded to routine
anticoagulant therapy. There were no long-term sequelae.
Cardiac perforation. Symptomatic and thus clinically
recognizable cardiac perforationoccurred during one initial
study and one follow-up drug study. In the initial study,
catheters were in the right atrium, His bundle recording
position and right ventricular apex. During ventricular stim-
ulation and without apparent patient movement, the patient
complained of chest pressure and her blood pressure became
unobtainable within 5 minutes. Classic signs and fluoro-
scopic evidence of cardiac tamponade appeared. Pericar-
diocentesis confi rmed the diagnosis and blood was removed
at a rate of 50 cc/min for approximately 15 to 20 minutes.
Blood pressure was maintained with fluids and plasma ex-
panders. Within 10 minutes of reversal of anticoagulation
with protamine all pericardial drainage stopped. There were
no sequelae.
In a fo llow-up study in another patient. catheters were
positioned in the right atrium and right ventricular apex.
The patient developed chest pain and hypotension. The blood
pressure normalized with saline solution and albumin and
an echocardiogram revealed pericardial effusion; however,
no further therapy was required and the patient underwent
a subseqeunt study without incident a week later.
Neither patient who had symptomatic and clinically de-
tectable perforation had right ventriculardamage detectable
by noninvasive or invasive tests.
Hypotension. During or after study, 20 patients devel-
oped symptomatic hypotension (50 to 86 mm Hg systolic)
that was not related to an arrhythmiaand requiredtreatment.
In II patients, this was caused by intravenous antiarrhyth-
mic drug administration (procainamide in nine patients,
mexiletine and quinidine in one patient each). In nine pa-
tients, the hypotension was due to a vagal reaction during
catheter insertion or withdrawal. All episodes responded to
46
59
100
289
132
52
678*
No. of
Patients
Incidence/I ,OOO Incidence/
Complication Patients Exposed Procedure
Death 1(0.1%) 1/2,210 (0.05%)
Vascular 12 (1.2%) 12/1.782* (0.7%)
Arterial injury 4 (0.4%) 4/1,782 (0.2%)
Thrombophlebitis 6 (0.6%) 6/1,782 (0.3%)
Severe hematoma 2 (0.2%) 211 ,782 (0.1%)
Embolic 4 (0.4%) 4/2,210 (0.2%)
Systemic arterial 1 (0.1%) 112.210 (0.5%)
embolus
Pulmonary embolus 3 (0.3%) 3/2,210 (0.15%)
Cardiac perforation 2 (0.2%) 2/1.782 (0.1%)
Hypotension 20 (2%) 20/2,210 (1%)
There were no deaths after the conclusion of any initial
study or during or after any drug study.
Vascular complications. Arterial complications oc-
curred in four patients. None were observed in patients
undergoing arterial catheterization. In two patients, inad-
vertent puncture of the superficial femoral artery produced
a pseudoaneurysm that required surgical repair. In one pa-
tient, the anterior and posterior walls of this artery were
laceratedand hemostasis couldnotbe obtainedafter removal
of catheters; these lacerations were surgically repaired . In
the fourth patient, an in situ thrombus in the superficial
femoral artery developed the day after an initial study. At
surgical exploration, the artery was not injured and a fresh
thrombus was found. It was postulated that pressure used
to obtain hemostasis may have caused internal injury that
resulted in the thrombus. All four patients recovered after
surgery and there was no evidence of chronic arterial in-
sufficiency in any patient.
Thrombophlebitis occurred in six patients. In two pa-
tients it occurred after the initial procedure. The other four
patients had three to five procedures involving catheter in-
sertions and the phlebitis occurred after the third, fourth
Total
Atrial fibrillat ion
Atrial flutter
Supraventricular tachycardia
Sustained ventricular tachycardia
Nonsustained ventricular tachycardia
Ventricular fibrillation
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administration of saline solution , albumin or atropine , or
combinations, and there were no sequelae.
Miscellaneouscomplications. Threepatients developed
frequent angina unrelated to arrhythmias or pacing during
the studies andtheirstudies wereterminated. Theseepisodes
responded to routine therapy. No patient developed acute
myocardial infarction asa resultofelectrophysiologic study.
One patient developed an urticarial reaction to intrave-
nous procainamide infusion and two patients had an hys-
terical conversion reaction. There were no sequelae and no
infections, sepsis, or pyrogenic reactions .
Arrhythmic complications. Arrhythmias initiated by
programmed electrical stimulation or cathetermanipulation
were considered complications if they were not clinically
relevant to the patient's indication for study or failed to
respond to routine therapy. Thus, not all arrhythmias in-
duced during these studies were considered complications.
In one patient being evaluatedfor syncope and suspected
AV conduction disturbance , complete AV block occurred
during catheter placement. AV conduction did not return
and a permanent pacemaker was implanted. Syncope has
notrecurred in the 15months sincepacemaker implantation.
In four patients , ventricular fibrillation that was not rel-
evant to the patient's indication for study was initiated by
programmed stimulation. In each patient, the arrhythmia
wasinitiated bydoubleextrastimuli (triple extrastimuli were
used only in patients undergoing evaluation for ventricular
arrhythmias and in such patients, ventricular fibrillation was
not considered a complication) . In all patients , a single
countershock restored sinus rhythm and there were no se-
quelae.
In 14 patients who had a history ofsustained ventricular
tachycardia or cardiac arrest and who were in stable con-
dition without frequent episodes of malignant arrhythmia,
incessant ventricular tachycardia occurred during electro-
physiologic studies. In each patient, the incessant arrhyth-
mia followed the initiation of ventricular tachycardia by
programmed stimulation. In two patients, this event oc-
curred during the initial study when the patient was not
receiving antiarrhythmic drugs. In theother 12patients these
events occurred during drug evaluations (oral flecainide in
three; intravenous procainamide in three; intravenous in-
decainide, intravenous pirmenol, intravenous amiodarone,
oral disopyramide with intravenous mexiletine, oral amio-
daroneand oral amiodarone and procainamide in oneeach).
These episodes required prolonged treatment with fluids,
pressor agents, other antiarrhythmic agents, and pacing or
cardioversion, or both. All patients survived and there were
no permanent sequelae. This complication, development of
incessant ventricular tachycardia during electrophysiologic
drug evaluation, occurred in 12 (3%) of 397 patients with
a sustained ventricular tachyarrhythmia whounderwent drug
studies. These 12 episodes represent I% of the 1,081 drug
evaluations performed in patients with inducible sustained
ventricular tachyarrhythmias.
Atrial fibrillation that was not related to the patient's
clinical arrhythmia history and required drugs or cardio-
version for restoration of sinusrhythm wasinitiated bycath-
eter manipulation or programmed stimulation in 10patients.
The patients were not severely symptomatic; however, if
the atrialfibrillation prevented completion of thestimulation
protocol or persisted for several hours, it was converted
withdrugs (seven patients) or cardioversion (threepatients) .
Cardioversion. Electrical cardioversion was required to
terminate induced arrhythmias in 217 patients. In addition
to the three patients with atrial fibrillation noted earlier,
cardioversion was required for 289 episodes of sustained
ventricular tachycardia (in 166 patients) and 83 episodes of
ventricular fibrillation (in 48 patients) . In the 372 episodes
of ventricular tachycardia or fibrillation, cardioversion was
successful on the first shockin 275 (74%), the second shock
in77 (21 %)andthe thirdshockin 14(3.5%). In six patients,
more thanthreeshocks wererequired to terminate the tachy-
arrhythmia. Because of the difficulty in determining the
efficacy of cardioversion in patients with incessant ventric-
ular tachycardia, the patients with this arrhythmia (supra
vide) are not included in this analysis.
In patients with inducible sustained ventricular tachy-
cardia or fibrillation, cardioversion was required in 179
(53%) of 339 initial studies. In 80 of these 179 patients,
cardioversion was not required during any subsequent drug
evaluations. On the otherhand, it was required at leastonce
during follow-up drug studies in 35 patients in whomit was
not necessary during the initial study.
Discussion
Theusefulness ofclinical cardiac electrophysiologic studies
has been well established (1-9). They have been used to
diagnose previously undocumented arrhythmias and eval-
uatepharmacologic , deviceandsurgical therapies inpatients
with supraventricular and ventricular tachyarrhythmias
(2-9,11-15). Although many patients who undergo these
studies haveserious organic heartdisease, the riskof serious
complication is low. Particularly in patients with malignant
ventricular tachyarrhythmias , in whom the impact of re-
currentarrhythmia is significant, therisksandcomplications
of electrophysiologic testing are acceptable.
Comparison with previous studies. In general, our re-
sults confirm the report of DiMarco et al. (16) that electro-
physiologic studies carry an acceptably low incidence of
serious complication. The major differences in our ap-
proaches involve the use of indwelling electrode catheters
and systemic anticoagulation.
Dimarco et al. (16) and other laboratories (6) favor the
use of indwelling catheters to facilitate serial drug testing .
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Because of consideration for patient comfort, these catheters
were frequently inserted by way of the subclavian route.
This practice was associated with a small risk of pneumo-
thorax (1.6%). Moreover, indwelling catheters pose a risk
of local and systemic infection, also reported by DiMarco
et al. (16). We chose not to employ indwelling catheters
and thus avoid these complications. Moreover, our routine
use of stimulation of the right ventricular outflow tract in
patients with ventricular tachyarrhythmias was not readily
accomplished with an indwelling catheter. Nonetheless , the
superiority of either approach has not been clearly dem-
onstrated .
To avoid significant thromboembolic complications we
have routinely used systemic anticoagulation during studies.
DiMarco et al. (16) used heparin only when the left atrium
or ventricle was catheterized. Whether the use of heparin
or the avoidance of indwelling catheters explains the lower
incidence of venous thromboembolic complications in our
series (0.6 versus 2.5 %) is uncertain .
In a retrospective survey from six active electrophysi-
ology laboratories (17), the incidence of major complica-
tions related to the mechanical aspects of this procedure
were similar to those reported by DiMarco et al. (16) and
those in the present study . Although the cooperative study
was retrospective and included data from laboratories using
differing techniques and protocol s, it confirms the safety of
clinical electrophysiologic studies.
We have reported a higher incidence of artery injury than
others. This may be related to the frequent insertion of two
catheters in the same femoral vein, which may increase the
chance of inadvertently injuring the adjacent femoral artery .
Deaths during electrophysiologic studies. Few deaths
have been reported in previous clinical cardiac electro-
physiologic studies. In addition to the four deaths reported
in the multicenter study (17) and the death in the present
series, only one other well described case has been men-
tioned (18) . The patients who died typically were severely
ill with marked ventricular dysfunction , and several were
at the point of death at the time of study . However , the
potential lethality of perforation , emboli sm and proarrhyth-
mia should not be underestimated .
Arrhythmic complications. Although the arrhythmic
complications of electrophysiologic studies have been re-
ported (6,19) they have not been emphasized . The risk of
death is low but not absent and the proarrhythmic effects
of antiarrhythmic drugs present an additional hazard . In our
series, 12 (3%) of 397 patients with inducible malignant
ventricular tachyarrhythmias who underwent drug evalua-
tions had a severe proarrhythmic event , incessant ventricular
tachycardia . Although none of these patients died , that pos-
sibility was very real. Moreover , 35 patients who did not
have cardioversion during initial studies had ventricular
tachycardia that required cardioversion during drug studies.
Although the benefits of serial drug evaluations are appre-
ciable , their risks should not be minimized.
Comparison with angiographic catheterization. The
risks and complications of electrophysiologic studies re-
ported by us and others (16-20) are generally comparable
with those reported for coronary arteriography and cardiac
catheterization (21-28) . Although the specific types of com-
plications are somewhat different and mortality may be higher
for cardiac catheterization, the overall risk of both proce-
dures is acceptable . Data on complications of cardiac cath-
eterization have been compiled in large groups of patients
(5,000 to 50,000) in both university centers (23,26-28) and
community hospitals (24-27). Similar large groups from
diverse types of hospital facilities are required before we
can confidently assess the risks of electrophysiologic studies
in all hospital settings.
Conclusions. The incidence of catheterization-related
and arrhythmic complications of electrophysiologic studies
is low and acceptable. The roles of systemic anticoagulation
and indwelling catheters remain to be clarified although it
does appear that the incidence of thromboembolic compli -
cations can be reduced from that in previous reports. The
present data were collected in a university center tertiary
care facility and can be applied to similiar medical insti-
tutions; however , similiar data should be obtained from
other settings in which electrophysiologic studies may be
performed .
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